Want to see HLSQ full AI Analyst Report?
HLSQ Stock Chart & Stats
$0.13
<$0.01(4.44%)
At close: 4:00 PM EDT
$0.13
<$0.01(4.44%)
Day’s Range― - ―
52-Week Range$0.92 - $122.93
Previous Close$0.18
VolumeN/A
Average Volume (3M)400.43K
Market Cap
$2.92M
Enterprise Value$19.66
Total Cash (Recent Filing)$572.00K
Total Debt (Recent Filing)$3.37M
Price to Earnings (P/E)―
Beta0.01
Next Earnings
Nov 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-200.60
Shares Outstanding2,730,000
10 Day Avg. Volume911,586
30 Day Avg. Volume400,426
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-100.26
Price to Sales (P/S)0.00
P/FCF Ratio-4.95
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-58.5
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Enrollment Progress In EuropeEnrollment in European sites continues ahead of plan, supporting patient recruitment momentum while the U.S. study is on hold.
Regulatory Support And Commercial Opportunity For BX011Positive FDA feedback and guidance support advancing BX011 into a Phase 2a study for diabetic foot infections, offering access to a larger patient population and greater commercial potential.
Trial Continuity And Safety OversightIndependent data monitoring committee recommended continuation of the BX004 cystic fibrosis study with protocol amendments, indicating oversight confidence in managing observed adverse events.
Bears Say
Delayed Top-line Data Increasing Financing RiskPostponement of expected cystic fibrosis topline data pushes results later and amplifies the company's financing risk.
Financing And Liquidity RiskSecuring additional financing is a stated priority, reflecting potential liquidity constraints that could affect program advancement.
Regulatory Hold Due To Device ScrutinyFDA inquiries about a third-party nebulizer have placed the U.S. cystic fibrosis study on hold, creating regulatory uncertainty about trial continuation.
Tessera Defense and Homeland Security News
HLSQ FAQ
What was Tessera Defense and Homeland Security’s price range in the past 12 months?
Tessera Defense and Homeland Security lowest stock price was $0.92 and its highest was $122.93 in the past 12 months.
What is Tessera Defense and Homeland Security’s market cap?
Tessera Defense and Homeland Security’s market cap is $2.92M.
When is Tessera Defense and Homeland Security’s upcoming earnings report date?
Tessera Defense and Homeland Security’s upcoming earnings report date is Nov 12, 2026 which is in 57 days.
How were Tessera Defense and Homeland Security’s earnings last quarter?
Currently, no data Available
Is Tessera Defense and Homeland Security overvalued?
According to Wall Street analysts Tessera Defense and Homeland Security’s price is currently Overvalued.
Does Tessera Defense and Homeland Security pay dividends?
Tessera Defense and Homeland Security does not currently pay dividends.
What is Tessera Defense and Homeland Security’s EPS estimate?
Tessera Defense and Homeland Security’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tessera Defense and Homeland Security have?
Tessera Defense and Homeland Security has 2,730,000 shares outstanding.
What happened to Tessera Defense and Homeland Security’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tessera Defense and Homeland Security?
Currently, no hedge funds are holding shares in HLSQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tessera Defense and Homeland Security
Tessera Defense & Homeland Security, Inc. operates as a clinical-stage microbiome company, which engages in the development of both natural and engineered phage cocktails designed to target and destroy harmful bacteria in chronic diseases, such as cystic fibrosis and atopic dermatitis. Its product pipelines include BX004 and BX005, which are treatments for cystic fibrosis and atopic dermatitis respectively. The company was founded in March 2015 and is headquartered in Dover, DE.